Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction (PROTECT-ICD): Trial Protocol, Background and Significance - 08/10/16

Doi : 10.1016/j.hlc.2016.04.007

Sarah Zaman, MBBS, PhD ^a,^b, Andrew J. Taylor, MBBS, PhD ^c,^d, Martin Stiles, MBChB, PhD ^e, Clara Chow, MBBS, PhD ^f,^g,^h, Pramesh Kovoor, MBBS, PhD ^f,^g,^⁎
^a MonashHEART, Monash Medical Centre, Melbourne, Vic, Australia
^b Monash University, Melbourne, Vic, Australia
^c Department of Cardiology, The Alfred Hospital, Melbourne, Vic, Australia
^d Baker IDI Heart and Diabetes Institute, Melbourne, Vic, Australia
^e Waikato Hospital, Hamilton, New Zealand
^f Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia
^g The University of Sydney, Sydney, NSW, Australia
^h The George Institute for Global Health, Sydney, NSW, Australia

^⁎Corresponding author at: Cardiology Department, Westmead Hospital, Westmead, NSW, Australia, 2145. Tel.: +61298456511; fax: +61298458323

Riassunto

The ‘Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction’ (PROTECT-ICD) trial is an Australian-led multicentre randomised controlled trial targeting prevention of sudden cardiac death in patients who have at least moderately reduced cardiac function following a myocardial infarct (MI). The primary objective of the trial is to assess whether electrophysiological study to guide prophylactic implantation of an implantable cardioverter-defibrillator (ICD) early following MI (first 40 days) will lead to a significant reduction in sudden cardiac death and non-fatal arrhythmia. The secondary objective is to assess the utility of cardiac MRI (CMR) in assessing early myocardial characteristics, and its predictive value for both inducible ventricular tachycardia (VT) at EPS and SCD/ non-fatal arrhythmia at follow-up.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Sudden cardiac death, Primary prevention, Myocardial infarction, Implantable-cardioverter defibrillator, Randomised controlled trial

Mappa

Esportazione

Vol 25 - N° 11

P. 1055-1062 - novembre 2016 Ritorno al numero

Articolo precedente

Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes
Karam Kostner, Stephen Nicholls, John Amerena, Alex Brown, Mark Cooper, Chris Hammett, Richard O’Brien, Leonard Kritharides, David L. Hare, Gerald F. Watts, Philip Aylward, Karam Kostner, Stephen Nicholls, John Amerena, Alex Brown, Mark Cooper, Chris Hammett, Richard O’Brien, Leonard Kritharides, David L. Hare, Gerald F. Watts, Philip Aylward

| Articolo seguente

Veno-Arterial ECMO in the Setting of Post-Infarct Ventricular Septal Defect: A Bridge to Surgical Repair
Aden McLaughlin, David McGiffin, James Winearls, Peter Tesar, Christopher Cole, Michael Vallely, Andrew Clarke, John Fraser

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

connettersi o creare un account

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction (PROTECT-ICD): Trial Protocol, Background and Significance - 08/10/16

Riassunto

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL